



## COMPANY OVERVIEW

Cerecor is an integrated biopharmaceutical company developing innovative therapies at the cutting edge of science. Our pipeline, filled with forward-thinking ideas, propels us forward. We are driven to change the lives of patients with rare orphan diseases in pediatrics and neurology.

## RECENT NEWS

### FDA Accepts IND Application for Cerecor's Investigational Drug CERC-801 for the treatment of PGM1 Deficiency

Jan 22 2019, 6:30 AM EST

### FDA Grants Cerecor's Three Substrate Replacement Therapies Orphan Drug Designation

Jan 16 2019, 6:30 AM EST

## STOCK OVERVIEW

Symbol	CERC
Exchange	Nasdaq
Market Cap	213.41m
Last Price	\$5.23
52-Week Range	\$2.71 - \$5.90

01/23/2019 04:00 PM EST

## INVESTOR RELATIONS

[ir@cerecor.com](mailto:ir@cerecor.com)

## MANAGEMENT TEAM

### Peter Greenleaf

Chief Executive Officer

### Joe Miller, CPA

Chief Financial Officer

### Matthew V. Phillips

Chief Commercial Officer

### Perry Calias, Ph.D.

Chief Scientific Officer | Head of R&D

### James A. Harrell, Jr.

Executive Vice President, Marketing and External Communications

### Patrick J. Crutcher

Vice President, Business Development

## CERECOR, INC.

540 Gaither Road  
Suite 400  
Rockville, MD 20850

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.